| Protein Name | Purinergic receptor P2Y14 |
| Gene Name | P2RY14 |
| Uniprot | Q15391 (Human); Q9ESG6 (Mouse) |
| Synonym | P2Y14; BPR105; GPR105; P2Y purinoceptor 14; G protein coupled receptor for UDP-glucose; G-protein coupled receptor 105; P2Y(14) receptor; P2Y14 receptor; UDP-glucose receptor; purinergic receptor P2Y, G-protein coupled, 14 |
| Background | P2RY14 is encoded by P2RY14 gene. It belongs to the G-protein-coupled receptor (GPCR) family which has been reported to regulate a panoply of cell signaling and physiologic responses. P2RY14 is one of the eight-member family of nucleotide-activated P2Y receptors and it is activated by UDP-glucose and other nucleotide sugars. It is also known as UDP glucose receptor because UDP glucose, UDP galactose, and UDP-N-acetylglucosamine are identified as potent agonists of P2RY14. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX74 | NativeExtract™ Human P2RY14 Membrane Protein (Full length, Super Nanodisc) | HEK293 cell | Full length | Native Nanodisc |
| MPX3373K | MemDX™ Membrane Protein Human P2RY14 Expressed in vitro E.coli expression system, Full Length | E.coli cell-free | Full length | Detergent |
| MP0994X | MemDX™ Membrane Protein Human P2RY14 (Purinergic receptor P2Y14) for Antibody Discovery | Wheat germ cell-free | Full length | N/A |
| Please for more products or customization | ||||
T***in: The tailored P2RY14 expression system delivered intact tertiary structure preservation.
08/Nov/2023
We provide tailored solutions to meet your specific requirements. Please for more services.
AAV-Mediated siRNA Silencing of P2RY14 in Inflammatory Pathologies
Creative Biolabs offers AAV-mediated siRNA silencing services. Recombinant adeno-associated virus (AAV) vectors engineered with small interfering RNA (siRNA) payloads enable selective downregulation of P2RY14 expression in diseased tissues. For instance, preclinical studies demonstrate that AAV9-based delivery of P2RY14-targeting siRNAs effectively attenuates intestinal epithelial cell necroptosis in murine colitis models by suppressing RIPK1 transcription via cAMP/PKA/CREB axis modulation. Creative Biolabs' expertise in designing tissue-specific AAV serotypes ensures precise transduction of colonic epithelial cells while minimizing off-target effects, a critical consideration for clinical translation.
P2RY14 Gene Editing for Hyperactivation Mitigation
Creative Biolabs offers P2RY14 gene editing services. Gene editing systems optimized for single-nucleotide precision permit permanent inactivation of gain-of-function P2RY14 mutations linked to chronic inflammation. Creative Biolabs' proprietary screening platforms validate guide RNA specificity and off-target profiles, ensuring therapeutic accuracy.
Creative Biolabs offers comprehensive and innovative services to drive the development of P2RY14 cell therapy. Please for more services.
Engineered Macrophages with P2RY14 Antagonist-Secreting Capabilities
Creative Biolabs offers engineered macrophages with P2RY14 antagonist-secreting capabilities development services. Autologous macrophages genetically modified to secrete P2RY14 antagonists, such as HDL-16, offer a sustained therapeutic effect in inflamed microenvironments. These cells are transduced with lentiviral vectors encoding antagonist expression cassettes under control of hypoxia-responsive promoters, enabling localized drug release in ischemic colonic regions. Creative Biolabs' immunofluorescence-based validation services rigorously assess antagonist secretion kinetics and target engagement in 3D organoid co-culture systems.
P2RY14-Inhibitory CAR-T Cells for Immune-Mediated Disease Control
Creative Biolabs offers P2RY14-inhibitory CAR-T cells development services for immune-mediated disease control. Chimeric antigen receptor (CAR)-T cells targeting extracellular P2RY14 epitopes exhibit potent immunosuppressive activity in autoimmune disorders. By fusing a P2RY14-specific single-chain variable fragment (scFv) to intracellular NFAT signaling domains, these CAR-T cells selectively deplete P2RY14-overexpressing immune cells while sparing healthy tissues. Creative Biolabs' vector production infrastructure accelerates the transition from preclinical validation to clinical-scale manufacturing.
The complexities of P2RY14-targeted gene and cell therapies demand unparalleled technical precision. Creative Biolabs' integrated platform combines AI-driven target validation, proprietary vector engineering, and translational assay development to de-risk your drug development pipeline. to design a bespoke strategy addressing your therapeutic goals.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.